Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 22 September 2023, including: Novartis AG gives back BeiGene, Ltd. PD-1; Bristol Myers Squibb Company revs R&D engine; Anthos Therapeutics Inc. changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe" - Scrip, 19 Sep, 2023.)
(Also see "BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually" - Scrip, 15 Sep, 2023.)
(Also see "Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First" - Scrip, 18 Sep, 2023.)
(Also see "Taking On Obesity The Hard Way" - Scrip, 20 Sep, 2023.)
(Also see "Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In" - Scrip, 19 Sep, 2023.)